Summit Therapeutics plc (SMMT) News
Filter SMMT News Items
SMMT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SMMT News Highlights
- SMMT's 30 day story count now stands at 2.
- Over the past 15 days, the trend for SMMT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- III are the most mentioned tickers in articles about SMMT.
Latest SMMT News From Around the Web
Below are the latest news stories about Summit Therapeutics Inc that investors may wish to consider to help them evaluate SMMT as an investment opportunity.
We Think Summit Therapeutics (NASDAQ:SMMT) Needs To Drive Business Growth CarefullyJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
Summit Therapeutics Announces Postponement of Its Planned Rights OfferingCambridge, Massachusetts, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced the postponement of its previously announced rights offering to stockholders of record on February 4, 2022. The Company had previously announced topline results for its Phase III Ri-CoDIFy study evaluating ridinilazole for the treatment of and Sustained Clinical Response (“SCR”) for patients suffering from C. difficile infection ("C. diff. infection" or |
Summit Therapeutics Announces Rights OfferingCambridge, Massachusetts, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that the Company’s Board of Directors has approved a rights offering available to all holders of record of the Company’s common stock, par value $0.01 (the “Common Stock”) as of the close of the market on February 4, 2022 (the “Record Date”). The Company intends to distribute to all holders of Common Stock as of the Record Date non-transferable subscript |
Summit Therapeutics Today Presents Its Company Vision at 40th Annual J.P. Morgan Healthcare Virtual ConferenceCambridge, Massachusetts, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) reminds interested stakeholders that it will today present the Company’s vision and its intended future development pathways at the 40th Annual J.P. Morgan Healthcare Conference at approximately 3:45 PM EST. Robert W. Duggan, Chairman and Chief Executive Officer, and Dr. Maky Zanganeh, Chief Operating Officer and a member of Summit’s Board of Directors, will provide det |
Summit Therapeutics to Present Company Vision at 40th Annual J.P. Morgan Healthcare Virtual ConferenceCambridge, Massachusetts, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that it will present the Company’s vision and its intended future development pathways at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at approximately 3:45 PM EST. Robert W. Duggan, Chairman and Chief Executive Officer, and Dr. Maky Zanganeh, Chief Operating Officer and a member of Summit’s Board of Directors, will prov |
ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Summit Therapeutics Inc. with Losses of $100,000 to Contact the FirmThe Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or "the Company") (NASDAQ: SMMT) for violations of the securities laws. |
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Summit Therapeutics Inc. with Losses of $100,000 to Contact the FirmLOS ANGELES, December 28, 2021--INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Summit Therapeutics Inc. with Losses of $100,000 to Contact the Firm |
Investigation Alert: Did You Lose Money on Your Investment? Johnson Fistel, LLP Encourages Investors to Contact the FirmShareholder rights law firm Johnson Fistel, LLP, is investigating potential claims against the following Companies for violations of federal securities laws. |
H.C. Wainwright Remains a Hold on Summit Therapeutics (SMMT)In a report released today, Ed Arce from H.C. Wainwright maintained a Hold rating on Summit Therapeutics (SMMT – Research Report). The company's shares closed last Monday at $2.59. According to TipRanks.com, Arce is a 5-star analyst with an average return of 15.6% and a 41.1% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Paratek Pharmaceuticals. The word on The Street in general, suggests a Hold analyst consensus rating for Summit Therapeutics. See the top stocks recommended by analysts >> The company has a one-year high of $12.30 and a one-year low of $4.42. |
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Summit Therapeutics Inc. (SMMT) InvestigationNEW YORK, NY / ACCESSWIRE / December 21, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ:SMMT). |